Chang Mei-Yin, Chong Inn-Wen, Chen Fang-Ming, Wang Jaw-Yuan, Cheng Tian-Lu, Cheng Yu-Jen, Sheu Chau Chyun, Hung Sung-Yu, Yang Ming-Chen, Lin Shiu-Ru
MedicoGenomic Research Center, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung 807, Taiwan, ROC.
Cancer Lett. 2005 May 26;222(2):195-204. doi: 10.1016/j.canlet.2004.11.020. Epub 2004 Dec 23.
Extensive researches have found that the mutation of p53 tumor suppressor gene is the most frequent event in many human cancers and associated with a poor clinical outcome in lung cancer patients. Because the p53 molecular mutation involved in tumorigenesis of patients with lung cancer in Taiwan remains poorly defined, the aim of this study was to assess the p53 mutation spectrum and possible etiological factors of Taiwan's patients with Non-Small Cell Lung Cancer (NSCLC). Cancer specimens were obtained surgically from 61 patients with pathologically proven NSCLC. Polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and direct sequencing were used to study p53 mutations in exon 4-8. We also performed immunohistochemistry (IHC) to detect p53 protein expression. Our results provided that 34 mutations of p53 gene were found in 27 cases with a mutation rate of 44% (27/61). There were six cases having more than two p53 mutations. Among the 34 mutations, 19 were point mutations (56%, 19/34) consisted of a majority of missense mutations including transversion (13/19, 68%) and transitions (6/19, 32%) with four cases (4/6, 67%) occurring in the CpG sequence. One of the most important finding in our study was the high frequency of frameshift (44%, 15/34) which included 11 insertions and 4 deletions of p53 in NSCLC in Taiwan. Surprisingly, our results disclosed distinct novel mutations at codon 181, 185, 208 (Exon 5-6) of p53. Especially, 4 cases with mutation at codon181 and codon 185 seemed to have more advanced clinical outcome with survival time less than 6 months. In addition, there were two recurring mutations at codon 168 and three at condon193. The different mutation spectrum in our series, including a high frequency of frameshift mutations and distinctly novel hot spots suggested the heterogenous entity of exogenous mutagens in NSCLC in Taiwan.
广泛的研究发现,p53肿瘤抑制基因的突变是许多人类癌症中最常见的事件,并且与肺癌患者不良的临床预后相关。由于台湾肺癌患者肿瘤发生过程中涉及的p53分子突变仍不清楚,本研究的目的是评估台湾非小细胞肺癌(NSCLC)患者的p53突变谱及可能的病因。从61例经病理证实为NSCLC的患者手术获取癌组织标本。采用聚合酶链反应-单链构象多态性(PCR-SSCP)和直接测序法研究第4至8外显子的p53突变情况。我们还进行了免疫组织化学(IHC)检测p53蛋白表达。我们的结果显示,在27例患者中发现了34个p53基因突变,突变率为44%(27/61)。有6例患者存在两个以上的p53基因突变。在这34个突变中,19个是点突变(56%,19/34),其中大多数是错义突变,包括颠换(13/19,68%)和转换(6/19,32%),4例(4/6,67%)发生在CpG序列中。我们研究中最重要的发现之一是移码突变的高频率(44%,15/34),其中包括台湾NSCLC患者中p53的11个插入和4个缺失。令人惊讶的是,我们的结果揭示了p53第181、185、208密码子(第5至6外显子)处有明显的新突变。特别是,4例第181和185密码子发生突变的患者似乎临床预后更差,生存时间不到6个月。此外,第168密码子有两个复发突变,第193密码子有三个复发突变。我们研究系列中不同的突变谱,包括移码突变的高频率和明显的新热点,提示台湾NSCLC中外源诱变剂的异质性。